Overview

A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Moderate Alcohol Associated Hepatitis (Part 1)

Eligibility

Inclusion Criteria:

• Adult ≥ 21 years old on the day of signing the informed consent form;
• Clinical diagnosis of alcoholic hepatitis, based on clinical features and laboratory testing, confirmed by the Investigator at screening
• Agreement to abstain from alcohol and utilize resources to cease at-risk behaviors during the trial, including addiction/alcohol abuse treatment
• Ability and willingness to swallow tablets
• Willingness to provide signed informed consent, prior to any trial-related procedures and willingness to comply with the trial procedures and requirements

Exclusion Criteria:

• Pregnant, intending to become pregnant (or father a child), or breastfeeding
• Current or recent enrollment in another interventional trial in the 30 days prior to screening